Continuous Hyperfractionated Accelerated Radiotherapy (CHART) and Non-conventionally Fractionated Radiotherapy in the Treatment of Non-small Cell Lung Cancer: a Review and Consideration of Future Directions

被引:11
|
作者
Hatton, M. Q. F. [1 ]
Martin, J. E. [1 ]
机构
[1] Weston Pk Hosp, Dept Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England
关键词
Accelerated radiotherapy; CHART; chemoradiotherapy; non-small cell lung cancer; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; THERAPY-ONCOLOGY-GROUP; STEREOTACTIC BODY RADIOTHERAPY; HIGH-DOSE RADIATION; INDUCTION CHEMOTHERAPY; TUMOR-CONTROL; PHASE-I/II; HYPOFRACTIONATED RADIOTHERAPY; CLINICAL-OUTCOMES; MULTICENTER TRIAL;
D O I
10.1016/j.clon.2010.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is a well-established role for radiation treatment in the management of non-small cell lung cancer As a single modality, it is indicated as a radical treatment option for patients deemed unsuitable for chemotherapy with inoperable locoregional disease or who decline surgery In this patient group, the evidence shows advantages for accelerated treatment regimes, e g continuous hyperfractionated accelerated radiotherapy (CHART) Research efforts should be directed towards close escalation with the application of the new technologies available The multi-modality approach of chemoradiotherapy is established in the radical treatment of non-small cell lung cancer in those who are inoperable, radically treatable and Fit enough to receive chemotherapy How best these two modalities ale combined remains unclear, and the combination of CHART and other non-conventionally fractionated radiotherapy schedules with chemotherapy and targeted agents is another potentially productive research area (C) 2010 The Royal College of Radiologists Published by Elsevier Ltd All rights reserved
引用
收藏
页码:356 / 364
页数:9
相关论文
共 50 条
  • [31] Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non-small cell lung cancer: the MRC INCH randomised trial
    Matthew, Hatton
    Nankivell, Matthew G.
    Lyn, Ethan
    Falk, Stephen
    Pugh, Cheryl
    Navani, Neal
    Stephens, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S337 - S337
  • [32] The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer
    Holgersson, Georg
    Bergqvist, Michael
    Nyman, Jan
    Hoye, Even
    Helsing, Martin
    Friesland, Signe
    Holgersson, Margareta
    Ekberg, Lars
    Morth, Charlotte
    Ekman, Simon
    Blystad, Thomas
    Ewers, Sven-Borje
    Loden, Britta
    Henriksson, Roger
    Bergstrom, Stefan
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [33] Follow up of patients with lung cancer receiving radical radiotherapy: Continuous hyperfractionated accelerated radiotherapy (CHART) treatment
    Roy, K.
    Win, T.
    Williams, M.
    Lyn, E.
    LUNG CANCER, 2010, 67 : S29 - S30
  • [34] Utilization and Survival Impact of Definitive Hypofractionated Radiotherapy Compared to Conventionally Fractionated Radiotherapy in Stage I Non-Small Cell Lung Cancer
    Park, Henry
    Saeed, Nadia
    Decker, Roy
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (02): : E13 - E13
  • [35] Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less
    Wilson, EM
    Williams, FJ
    Lyn, BE
    Aird, EGA
    RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) : 307 - 314
  • [36] Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial
    Hechtner, Marlene
    Krause, Mechthild
    Koenig, Jochem
    Appold, Steffen
    Hornemann, Beate
    Singer, Susanne
    Baumann, Michael
    RADIOTHERAPY AND ONCOLOGY, 2018, 126 (02) : 283 - 290
  • [37] Continuous hyperfractionated accelerated radiotherapy (CHART) using volumetric modulated arc therapy (VMAT) for locally advanced non-small cell lung cancer (NSCLC) - the clinical experience
    Shrimali, R.
    Sen, P.
    Arunsingh, M.
    Mahata, A.
    Mallick, I.
    Prasath, S.
    Achari, R.
    Chatterjee, S.
    LUNG CANCER, 2016, 91 : S43 - S44
  • [38] PROSPECTIVE DATA OF CONTINUOUS HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (CHART) FOR NON-SMALL CELL LUNG CANCER (NSCLC): CLINICAL OUTCOME AND PATIENT SATISFACTION SURVEY OF THE NORTHERN REGIONAL CANCER CENTRE
    Loo, H. W.
    Klapper, R.
    Mulvenna, P.
    McMenemin, R.
    McDonald, F.
    Atherton, P.
    Mazdai, G.
    THORAX, 2009, 64 : A83 - A83
  • [39] A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer
    Zhang, Weisan
    Liu, Qian
    Dong, Xifeng
    Lei, Ping
    JOURNAL OF THORACIC DISEASE, 2015, 7 (03) : 478 - 485
  • [40] 73.6 Gy and beyond: Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer
    Maguire, PD
    Marks, LB
    Sibley, GS
    Herndon, JE
    Clough, RW
    Light, KL
    Hernando, ML
    Antoine, PA
    Anscher, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 705 - 711